Literature DB >> 19190126

Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy.

Maria Quanz1, Nathalie Berthault, Christophe Roulin, Maryline Roy, Aurélie Herbette, Céline Agrario, Christophe Alberti, Véronique Josserand, Jean-Luc Coll, Xavier Sastre-Garau, Jean-Marc Cosset, Lionel Larue, Jian-Sheng Sun, Marie Dutreix.   

Abstract

PURPOSE: Enhanced DNA repair activity is often associated with tumor resistance to radiotherapy. We hypothesized that inhibiting DNA damage repair would sensitize tumors to radiation-induced DNA damage. EXPERIMENTAL
DESIGN: A novel strategy for inhibiting DNA repair was tested. We designed small DNA molecules that mimic DNA double-strand breaks (called Dbait) and act by disorganizing damage signaling and DNA repair. We analyzed the effects of Dbait in cultured cells and on xenografted tumors growth and performed preliminary studies of their mechanism(s) of action.
RESULTS: The selected Dbait molecules activate H2AX phosphorylation in cell culture and in xenografted tumors. In vitro, this activation correlates with the reduction of Nijmegen breakage syndrome 1 and p53-binding protein 1 repair foci formation after irradiation. Cells are sensitized to irradiation and do not efficiently repair DNA damage. In vivo, Dbait induces regression of radioresistant head and neck squamous cell carcinoma (Hep2) and melanoma (SK28 and LU1205) tumors. The combination of Dbait32Hc treatment and fractionated radiotherapy significantly enhanced the therapeutic effect. Tumor growth control by Dbait molecules depended directly on the dose and was observed with various irradiation protocols. The induction of H2AX phosphorylation in tumors treated with Dbait suggests that it acts in vivo through the induction of "false" DNA damage signaling and repair inhibition.
CONCLUSIONS: These data validate the concept of introducing small DNA molecules, which mimic DNA damage, to trigger "false" signaling of DNA damage and impair DNA repair of damaged chromosomes. This new strategy could provide a new method for enhancing radiotherapy efficiency in radioresistant tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190126     DOI: 10.1158/1078-0432.CCR-08-2108

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci.

Authors:  Maria Quanz; Aurélie Herbette; Mano Sayarath; Leanne de Koning; Thierry Dubois; Jian-Sheng Sun; Marie Dutreix
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

2.  Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.

Authors:  Flavien Devun; Guilhem Bousquet; Julian Biau; Aurélie Herbette; Christophe Roulin; Frédérique Berger; Jian-Sheng Sun; Sylvie Robine; Marie Dutreix
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

3.  Radiation-generated short DNA fragments may perturb non-homologous end-joining and induce genomic instability.

Authors:  Dalong Pang; Thomas A Winters; Mira Jung; Shubhadeep Purkayastha; Luciane R Cavalli; Sergey Chasovkikh; Bassem R Haddad; Anatoly Dritschilo
Journal:  J Radiat Res       Date:  2011       Impact factor: 2.724

Review 4.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

Authors:  Wael Jdey; Sylvain Thierry; Christophe Russo; Flavien Devun; Muthana Al Abo; Patricia Noguiez-Hellin; Jian-Sheng Sun; Emmanuel Barillot; Andrei Zinovyev; Inna Kuperstein; Yves Pommier; Marie Dutreix
Journal:  Clin Cancer Res       Date:  2016-08-24       Impact factor: 12.531

6.  Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models.

Authors:  Nirmitha I Herath; Flavien Devun; Aurélie Herbette; Marie-Christine Lienafa; Philippe Chouteau; Jian-Sheng Sun; Marie Dutreix; Alban Denys
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

7.  DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion.

Authors:  Ewa Kotula; Nathalie Berthault; Celine Agrario; Marie-Christine Lienafa; Anthony Simon; Florent Dingli; Damarys Loew; Vonick Sibut; Simon Saule; Marie Dutreix
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  New paradigms and future challenges in radiation oncology: an update of biological targets and technology.

Authors:  Stanley L Liauw; Philip P Connell; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

9.  FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Authors:  Qiudong Deng; Christopher J Holler; Georgia Taylor; Kathryn F Hudson; William Watkins; Marla Gearing; Daisuke Ito; Melissa E Murray; Dennis W Dickson; Nicholas T Seyfried; Thomas Kukar
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

10.  Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response.

Authors:  Maria Quanz; Danielle Chassoux; Nathalie Berthault; Céline Agrario; Jian-Sheng Sun; Marie Dutreix
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.